Literature DB >> 12811416

[Severe acute respiratory syndrome (SARS)].

Adrian Gillissen1, Bernhard R Ruf.   

Abstract

Severe acute respiratory syndrome (SARS) is a viral disease, observed primarily in Southern China in November 2002, with variable flu-like symptoms and pneumonia, in approx. 5% leading to death from respiratory distress syndrome (RDS). The disease was spread over more than 30 states all over the globe by SARS-virus-infected travelers. WHO and CDC received first information about a new syndrome by the end of February 2003, after the first cases outside the Republic of China had been observed. A case in Hanoi, Vietnam, led to the first precise information about the new disease entity to WHO, by Dr. Carlo Urbani, a co-worker of WHO/Doctors without Borders, who had been called by local colleagues to assist in the management of a patient with an unknown severe disease by the end of February 2003. Dr. Urbani died from SARS, as did many other health care workers. In the meantime, more than 7,000 cases have been observed worldwide, predominantly in China and Hong Kong, but also in Taiwan, Canada, Singapore, and the USA, and many other countries, and more than 600 of these patients died from RDS. Since the beginning of March 2003, when WHO and CDC started their activities, in close collaboration with a group of international experts, including the Bernhard-Nocht-Institute in Hamburg and the Department of Virology in Frankfurt/Main, a previously impossible success in the disclosure of the disease was achieved. Within only 8 weeks of research it was possible to describe the infectious agent, a genetically modified coronavirus, including the genetic sequence, to establish specific diagnostic PCR methods and to find possible mechanisms for promising therapeutic approaches. In addition, intensifying classical quarantine and hospital hygiene measures, it was possible to limit SARS in many countries to sporadic cases, and to reduce the disease in countries such as Canada and Vietnam. This review article summarizes important information about many issues of SARS (May 15th, 2003).

Entities:  

Mesh:

Year:  2003        PMID: 12811416      PMCID: PMC7082805          DOI: 10.1007/s00063-003-1271-z

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  3 in total

1.  Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.

Authors:  Mohamad Hesam Shahrajabian; Wenli Sun; Qi Cheng
Journal:  Hum Vaccin Immunother       Date:  2020-08-12       Impact factor: 3.452

2.  Critical care medicine for emerging Middle East respiratory syndrome: Which point to be considered?

Authors:  Viroj Wiwanitkit
Journal:  Indian J Crit Care Med       Date:  2015-09

3.  Severe acute respiratory syndrome epidemic and change of people's health behavior in China.

Authors:  Xiaodong Tan; Shiyue Li; Chunhong Wang; Xiaoqing Chen; Xiaomin Wu
Journal:  Health Educ Res       Date:  2004-05-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.